Novartis Shorted Rival Up To $47M In IP Royalties, Jury Told
An economist hired by a Daiichi Sankyo subsidiary testified during a California federal jury trial Wednesday that Novartis owes up to $47.2 million for selling a drug that infringes the subsidiary's...To view the full article, register now.
Already a subscriber? Click here to view full article